The pharmaceutical company's MariTide treatment performs well in a phase 2 study but not as well as Wall Street expected.
Kohl’s Corp (NYSE:KSS) shares plummeted nearly 20% in premarket trading Tuesday after the retailer reported disappointing third-quarter results and significantly lowered its full-year outlook, citing ...
U.S. stocks are hanging around their records as Wall Street takes Donald Trump’s latest talk about tariffs in stride, even if ...
Major stock indexes were mixed Tuesday morning as investors digested earnings reports from several retailers and awaited ...
Kohl's announced that CEO Tom Kingsbury is stepping down in January. He will be replaced by Ashley Buchanan, the current ...
Kohl's (NYSE: KSS) stock collapsed after the company reported mixed earnings for its fiscal third quarter of 2024 Tuesday ...
Kohl's (KSS) has lowered its annual forecast following weaker-than-expected third-quarter results, causing shares to drop by ...
Traders shouldn’t bet on another year of double-digit gains for U.S. stocks in 2025, analyst warns. Last night, ...
As Black Friday approaches, a long list of retailers delivered third-quarter reports on Tuesday. One jumped into an early ...